Tearsheet

Perspective Therapeutics (CATX)

Market Price (3/7/2026): $4.89 | Market Cap: $363.3 Mil
Sector: Health Care | Industry: Life Sciences Tools & Services

Perspective Therapeutics (CATX)

Market Price (3/7/2026): $4.89
Market Cap: $363.3 Mil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -46%	Weak multi-year price returns 2Y Excs Rtn is -79%, 3Y Excs Rtn is -34%	Very low revenue Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
1	Megatrend and thematic drivers Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.	Meaningful short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13%	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -95 Mil
2			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -33%
3			High stock price volatility Vol 12M is 120%

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -46%
1	Megatrend and thematic drivers Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.
2	Weak multi-year price returns 2Y Excs Rtn is -79%, 3Y Excs Rtn is -34%
3	Meaningful short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13%
4	Very low revenue Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
5	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -95 Mil
6	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -33%
7	High stock price volatility Vol 12M is 120%

Valuation, Metrics & Events

	3/7/26	2025	2024	2023	2022
Share Price CYE	$4.89	$2.75	$3.19	$4.02	$2.47
Market Cap CYE ($ Mil)	363.3	204.3	225.3	11.3	35.1
Total Debt ($ Mil)	3.3	3.3	4.3	3.3	0.5
Total Cash ($ Mil)	174.1	174.1	267.8	18.0	55.9
Enterprise Value ($ Mil)	192.5	207.6	229.6	14.6	35.6
Valuation Ratios
P/S TTM	-	-	-	6.6	3.3
P/EBIT TTM	-3.4	-1.9	-4.5	-0.3	-4.7
P/E TTM	-3.4	-1.9	-3.5	-0.4	-4.8
P/FCF TTM	-3.4	-1.9	-5.6	-0.4	-4.4
Sector Ratios
P/S TTM (Sector)	3.8	4.2	3.8	4.2	4.4
P/EBIT TTM (Sector)	-1.6	-1.6	-1.5	-1.3	-1.2
P/E TTM (Sector)	-1.8	-1.8	-1.7	-1.5	-1.2
P/FCF TTM (Sector)	-1.5	-1.5	-1.5	-1.3	-1.6

	3/7/26	2025	2024
Share Price CYE	$4.89	$2.75	$3.19
Market Cap CYE ($ Mil)	363.3	204.3	225.3
Total Debt ($ Mil)	3.3	3.3	4.3
Total Cash ($ Mil)	174.1	174.1	267.8
Enterprise Value ($ Mil)	192.5	207.6	229.6
Valuation Ratios
P/S TTM	-	-	-
P/EBIT TTM	-3.4	-1.9	-4.5
P/E TTM	-3.4	-1.9	-3.5
P/FCF TTM	-3.4	-1.9	-5.6
Sector Ratios
P/S TTM (Sector)	3.8	4.2	3.8
P/EBIT TTM (Sector)	-1.6	-1.6	-1.5
P/E TTM (Sector)	-1.8	-1.8	-1.7
P/FCF TTM (Sector)	-1.5	-1.5	-1.5

null

AI Analysis | Feedback

Metric	Value	Date	Source
Total Patients Dosed in [212Pb]VMT-α-NET Phase 1/2a Trial	55	9122025	Link
Objective Response Rate in [212Pb]VMT-α-NET Phase 1/2a Trial (Cohort 2)	44%	9122025	Link
Number of Clinical-Stage Radiopharmaceutical Therapies	3	5122025	Link
U.S. Manufacturing Facilities	2 operational, 3 in development	5122025	Link
Patent Portfolio Extension	Through 2041-2044	5122025	Link
Clinical Trial Collaborations	Bristol Myers Squibb, Lantheus Holdings, Mayo Clinic	9152025	Link

Upcoming
3/25/2026	Earnings Release	Rev: - EPS: -

Price Chart

Return (1M):

null

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Perspective Therapeutics (CATX) stock has gained about 110% since 11/30/2025 because of the following key factors:

1. Positive interim clinical trial data for [212Pb]VMT-α-NET in neuroendocrine tumors fueled investor optimism. The company reported updated interim Phase 1/2a results in January 2026, with data cut-off as of December 10, 2025, which showed a 39% objective response rate in Cohort 2 patients and 76% of patients remaining without progression and alive.

2. A substantial $175 million underwritten public offering significantly bolstered the company's financial position. In February 2026, Perspective Therapeutics announced the pricing of this offering, providing capital to advance its cancer radiopharmaceutical pipeline and extending its cash runway into late 2026.

Show more

Stock Movement Drivers

Fundamental Drivers

The 111.5% change in CATX stock from 11/30/2025 to 3/6/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).

(LTM values as of)	11302025	3062026	Change
Stock Price ($)	2.35	4.97	111.5%
Change Contribution By:
Total Revenues ($ Mil)	0	0	0.0%
P/S Multiple	∞	∞	0.0%
Shares Outstanding (Mil)	74	74	0.0%
Cumulative Contribution			0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

11/30/2025 to 3/6/2026

	Return	Correlation
CATX	111.5%
Market (SPY)	-1.6%	9.3%
Sector (XLV)	-3.1%	5.0%

Fundamental Drivers

The 47.9% change in CATX stock from 8/31/2025 to 3/6/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).

(LTM values as of)	8312025	3062026	Change
Stock Price ($)	3.36	4.97	47.9%
Change Contribution By:
Total Revenues ($ Mil)	0	0	0.0%
P/S Multiple	∞	∞	0.0%
Shares Outstanding (Mil)	74	74	-0.1%
Cumulative Contribution			0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

8/31/2025 to 3/6/2026

	Return	Correlation
CATX	47.9%
Market (SPY)	4.5%	1.6%
Sector (XLV)	11.6%	-1.5%

Fundamental Drivers

The 78.8% change in CATX stock from 2/28/2025 to 3/6/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).

(LTM values as of)	2282025	3062026	Change
Stock Price ($)	2.78	4.97	78.8%
Change Contribution By:
Total Revenues ($ Mil)	0	0	0.0%
P/S Multiple	∞	∞	0.0%
Shares Outstanding (Mil)	71	74	-4.9%
Cumulative Contribution			0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2025 to 3/6/2026

	Return	Correlation
CATX	78.8%
Market (SPY)	14.2%	22.4%
Sector (XLV)	3.9%	16.7%

Fundamental Drivers

The 36.2% change in CATX stock from 2/28/2023 to 3/6/2026 was primarily driven by a 9.2233720368547763E17% change in the company's P/S Multiple.

(LTM values as of)	2282023	3062026	Change
Stock Price ($)	3.65	4.97	36.2%
Change Contribution By:
Total Revenues ($ Mil)	10	0
P/S Multiple	5.2	∞	9.2233720368547763E17%
Shares Outstanding (Mil)	14	74	-80.9%
Cumulative Contribution			0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2023 to 3/6/2026

	Return	Correlation
CATX	36.2%
Market (SPY)	76.0%	17.9%
Sector (XLV)	25.7%	14.0%

Return vs. Risk

Price Returns Compared

	2021	2022	2023	2024	2025	2026	Total [1]
Returns
CATX Return	-14%	-36%	63%	-21%	-14%	85%	13%
Peers Return	18%	27%	13%	-14%	-9%	0%	33%
S&P 500 Return	27%	-19%	24%	23%	16%	-0%	82%
Monthly Win Rates [3]
CATX Win Rate	8%	50%	33%	50%	58%	67%
Peers Win Rate	45%	53%	45%	50%	53%	60%
S&P 500 Win Rate	75%	42%	67%	75%	67%	33%
Max Drawdowns [4]
CATX Max Drawdown	-16%	-43%	-17%	-29%	-46%	-15%
Peers Max Drawdown	-22%	-27%	-27%	-41%	-39%	-9%
S&P 500 Max Drawdown	-1%	-25%	-1%	-2%	-15%	-1%

[1] Cumulative total returns since the beginning of 2021
[2] Peers: LNTH, ATNM, CLRB, LLY, BMY.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/6/2026 (YTD)

How Low Can It Go

Unique Key	Event	CATX	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-91.7%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	1104.9%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-63.5%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	174.1%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	47 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-60.9%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	156.0%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	348 days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-97.1%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	3366.7%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	Not Fully Recovered days	1,480 days

Compare to LNTH, ATNM, CLRB, LLY, BMY

In The Past

Perspective Therapeutics's stock fell -91.7% during the 2022 Inflation Shock from a high on 1/20/2021. A -91.7% loss requires a 1104.9% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Perspective Therapeutics (CATX)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.

AI Analysis | Feedback

A specialized Novartis focused on developing next-generation radiopharmaceutical cancer treatments.
The BioNTech of radiopharmaceutical cancer therapies.

AI Analysis | Feedback

[212Pb]VMT-α-NET: This is Perspective Therapeutics' lead alpha-particle therapeutic candidate for treating neuroendocrine tumors.
[212Pb]PSMA TAT: This therapeutic candidate is being developed for the treatment of metastatic castration-resistant prostate cancer.
[212Pb]GRT: This therapeutic candidate targets specific solid tumors such as melanoma and small cell lung cancer.

AI Analysis | Feedback

Perspective Therapeutics (CATX) is a clinical-stage radiopharmaceutical company focused on developing targeted alpha-particle therapies for cancer. As of its latest public filings (e.g., 2023 10-K), the company does not have any products approved for commercial sale and has not generated revenue from product sales.

Consequently, Perspective Therapeutics does not currently have major commercial customers in the traditional sense of entities purchasing its products or services. Their operations are primarily focused on research and development, including conducting clinical trials to advance their therapeutic candidates. The company's funding primarily comes from equity financing and collaborations rather than sales revenue.

AI Analysis | Feedback

NorthStar Medical Radioisotopes, LLC (private company)

AI Analysis | Feedback

Thijs Spoor Chief Executive Officer

Thijs Spoor was appointed CEO in February 2023. He previously studied as a nuclear pharmacist over 30 years ago. Under his leadership, Perspective Therapeutics focuses on innovating cancer treatments using novel radiopharmaceuticals, specifically the alpha-emitting isotope Lead-212 (212Pb).

Joel Sendek Chief Financial Officer

Joel Sendek was appointed Chief Financial Officer effective September 4, 2025. He brings over 30 years of experience in the life sciences sector, having served as CFO at four prior biotech companies: Dewpoint Therapeutics, Sema4, Spero Therapeutics, and Forward Pharma. As CFO, he has a successful track record of raising over $2.5 billion in corporate transactions. His background also includes leadership roles as a senior equity research analyst at Stifel (Head of Healthcare Equity Research), Lazard, and Oppenheimer (Head of Healthcare Life Sciences Research), where he was recognized by The Wall Street Journal as an All-Star Analyst with a #1 ranking in stock picking.

Dr. Markus Puhlmann, MD MBA Chief Medical Officer

Dr. Markus Puhlmann is the Chief Medical Officer. He is a clinical researcher with over 30 years of combined experience in healthcare and the pharmaceutical industry, holding leadership positions in oncology drug development.

Jonathan Hunt Chief Accounting Officer

Jonathan Hunt serves as the Chief Accounting Officer. He previously held the role of Chief Financial Officer before the appointment of Juan Graham, and subsequently transitioned to Chief Accounting Officer.

Amos Hedt Chief Business Strategy Officer

Amos Hedt is the Chief Business Strategy Officer. He is a skilled strategist with over 20 years of biotechnology and pharmaceutical experience, providing comprehensive expertise across all stages of drug research and development.

AI Analysis | Feedback

null

AI Analysis | Feedback

A clear emerging threat for Perspective Therapeutics (CATX) is the advanced clinical development and potential market entry of directly competing alpha-emitting radiopharmaceuticals for neuroendocrine tumors (NETs).

Specifically, **RayzeBio's RYZ101 (Ac225-DOTATATE)**, now owned by Bristol Myers Squibb (BMS), represents a significant threat. RYZ101 is an alpha-particle radiopharmaceutical targeting SSTR2, which is the same indication (NETs) and mechanism of action as CATX's lead product candidate, Pb212-VMT-α-NET. RYZ101 is currently in a Phase 3 clinical trial (ACTION-1) for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Given BMS's acquisition of RayzeBio for $4.1 billion, there is substantial financial backing and commitment to commercializing RYZ101. If RYZ101 successfully completes its Phase 3 trial and gains regulatory approval, it could achieve market entry significantly earlier than CATX's Pb212-VMT-α-NET, and with the immense resources of BMS, could quickly capture market share, thereby diminishing the potential market opportunity for CATX's own lead asset.

AI Analysis | Feedback

Perspective Therapeutics (CATX) is involved in developing and commercializing radiopharmaceutical technologies for various cancer treatments. The addressable markets for their main products and pipeline candidates are substantial and predominantly global.

VMT-α-NET (Neuroendocrine Tumors - NETs): The global market for neuroendocrine tumor treatment was estimated to be between USD 2.66 billion and USD 3.56 billion in 2024. This market is projected to grow to a range of approximately USD 4.89 billion by 2034 to USD 7.87 billion by 2032. North America is a significant contributor to this market.
VMT01 (Melanoma): The global malignant melanoma treatment market was valued between USD 3.9 billion and USD 9.16 billion in 2023/2024. It is projected to reach between USD 8.9 billion and USD 21.79 billion by 2033/2034. North America holds a considerable share in the melanoma therapeutics market.
PSV4XX/PSMA Alpha-PET DoubLET (PSMA-expressing prostate cancers): The global prostate cancer therapeutics market was estimated between USD 12.9 billion and USD 17.0 billion in 2024/2025. This market is anticipated to grow to a range of USD 29.2 billion by 2035 to USD 31.99 billion by 2030. The global PSMA PET imaging and treatment market, a more specific segment relevant to PSV4XX, was valued at USD 0.91 billion in 2024 and is projected to reach USD 12.18 billion by 2033. North America is a dominant region in the prostate cancer therapeutics market.
CS-1 Cesium-131 Brachytherapy Seeds (for various cancers including prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers): The global brachytherapy market was valued between USD 0.99 billion and USD 1.33 billion in 2024, with projections to reach between USD 1.99 billion by 2034 and USD 2.22 billion by 2035. Specifically, the brachytherapy seeds market was valued at USD 137.7 million in 2024 and is predicted to reach USD 224.1 million by 2034. Prostate cancer represents a significant application segment within the brachytherapy market. North America leads the global brachytherapy market.
PSV359 (Solid Tumors targeting FAP-α): The global solid tumors market was valued between USD 170.3 billion and USD 362.21 billion in 2023/2024. It is projected to grow to a range of USD 375.4 billion by 2034 to USD 1557.42 billion by 2032. Fibroblast Activation Protein (FAP) is expressed in over 90% of malignant epithelial tumors. North America dominates the solid tumors market.

AI Analysis | Feedback

Perspective Therapeutics (CATX) is anticipated to drive future revenue growth over the next 2-3 years through several key initiatives focused on its innovative radiopharmaceutical pipeline and operational advancements.

Advancement and Commercialization of Lead Pipeline Candidates: A primary driver of future revenue growth for Perspective Therapeutics will be the successful progression and potential commercialization of its lead clinical programs. The company is actively developing VMT-α-NET for neuroendocrine tumors and VMT01 for metastatic melanoma, both of which are currently in Phase 1/2a clinical trials. Positive data from these trials and subsequent advancement through regulatory pathways toward market approval are critical for generating significant revenue.
Launch and Growth of New Products from the Pipeline: Beyond its lead programs, Perspective Therapeutics has other promising candidates in its pipeline, such as PSV359, which targets FAP-α in solid tumors, and PSV4XX, a differentiated prostate-specific membrane antigen-targeted alpha therapy. The company received Investigational New Drug (IND) clearance for PSV359, with patient dosing expected to commence in mid-2025. Successful development and eventual launch of these new products will broaden the company's product portfolio and create additional revenue streams.
Expansion of Target Indications for Radiopharmaceutical Therapies: The company's strategy involves expanding the range of tumors addressed by its radiopharmaceutical products. By focusing on targeted therapies that can treat various solid tumors, Perspective Therapeutics aims to increase its market positioning and offer new treatment options to a wider patient population. This expansion into additional indications could significantly increase the potential market size for its therapies.
Strengthening of Manufacturing and Supply Chain Capabilities: To support both ongoing clinical trials and future commercial operations, Perspective Therapeutics is actively expanding its manufacturing footprint. This includes establishing new facilities and enhancing its radioisotope supply chain to ensure a robust and reliable production and distribution network for its radiopharmaceutical therapies. The company has also developed a proprietary 212Pb generator to secure key isotopes, which is vital for the commercial viability and scale-up of its products.
Leveraging the Theranostic Approach for Personalized Treatment: Perspective Therapeutics is developing complementary imaging diagnostics alongside its therapeutic agents. This "theranostic" approach allows for the personalization of treatment by enabling physicians to visualize specific tumors and then deliver targeted radiation. This integrated approach has the potential to improve treatment efficacy and minimize toxicity, which could enhance market adoption and drive revenue growth by offering a more effective and tailored treatment solution.

AI Analysis | Feedback

Share Repurchases

Perspective Therapeutics, Inc. has a share repurchase program in place.

Share Issuance

The number of shares outstanding for Perspective Therapeutics increased by 67.21% in the last year.
As of October 15th, Perspective Therapeutics had issued a total of 74,260,000 shares.
The company executed a 1:10 reverse stock split on June 17, 2024.

Capital Expenditures

In the last 12 months, capital expenditures for Perspective Therapeutics were -$50.01 million.
Projected capital expenditures are $9 million for 2025, 2026, 2027, and 2028, increasing to $10 million in 2029.

Interactive Breakdown

null

null

Better Bets vs. Perspective Therapeutics (CATX)

null

Latest Trefis Analyses

	Title	Date
0	DASHBOARDS
1	Perspective Therapeutics Earnings Notes	12/16/2025
2	Day 6 of Loss Streak for Perspective Therapeutics Stock with -42% Return (vs. -9.7% YTD) [10/23/2025]	10/24/2025

	Title
0	ARTICLES

Trade Ideas

Select ideas related to CATX.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
QDEL_2282026_Insider_Buying_45D_2Buy_200K	02282026	QDEL	QuidelOrtho	Insider	Insider Buys 45DStrong Insider Buying Companies with multiple insider buys in the last 45 days	0.0%	0.0%	0.0%
CHE_2272026_Dip_Buyer_FCFYield	02272026	CHE	Chemed	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	0.0%	0.0%	0.0%
LLY_2272026_Monopoly_xInd_xCD_Getting_Cheaper	02272026	LLY	Eli Lilly	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	0.0%	0.0%	0.0%
HAE_2202026_Dip_Buyer_FCFYield	02202026	HAE	Haemonetics	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	3.5%	3.5%	0.0%
IQV_2132026_Dip_Buyer_ValueBuy	02132026	IQV	IQVIA	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	7.1%	7.1%	-3.0%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
DAWN	Day One Biopharmaceuticals	2.2	65.9%	127.5%
QURE	uniQure	0.8	34.0%	-40.4%
SLDB	Solid Biosciences	0.6	20.3%	19.7%
IOT	Samsara	20.3	19.5%	-0.3%
SWBI	Smith & Wesson Brands	0.6	18.7%	41.7%
MRVL	Marvell Technology	76.7	18.4%	5.5%
REPL	Replimune	0.7	14.6%	-17.0%
IOVA	Iovance Biotherapeutics	1.9	12.0%	87.9%
AMPX	Amprius Technologies	2.1	9.7%	107.0%
CAPR	Capricor Therapeutics	1.3	8.1%	-3.3%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
AXTI	AXT	1.4	-16.6%	98.0%
INGM	Ingram Micro	5.2	-16.3%	3.4%
BE	Bloom Energy	35.7	-15.5%	55.6%
GAP	Gap	8.7	-14.4%	-9.1%
NUTX	Nutex Health	0.6	-14.3%	-45.2%
LITE	Lumentum	39.7	-14.2%	51.5%
JEF	Jefferies Financial	8.2	-13.5%	-37.7%
MEOH	Methanex	3.9	-12.7%	25.5%
WOLF	Wolfspeed	0.4	-12.5%	-4.8%
RUM	Rumble	1.3	-12.5%	-22.3%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
DAWN	Day One Biopharmaceuticals	2.2	100.0%	127.5%
SOC	Sable Offshore	1.4	74.2%	59.3%
ZD	Ziff Davis	1.7	56.3%	20.4%
AMPX	Amprius Technologies	2.1	52.2%	107.0%
TNGX	Tango Therapeutics	1.9	52.2%	91.3%
BW	Babcock & Wilcox Enterprises	1.3	47.9%	106.6%
IOVA	Iovance Biotherapeutics	1.9	32.9%	87.9%
RCAT	Red Cat	1.5	31.8%	93.7%
VG	Venture Global	30.4	28.8%	83.0%
NMAX	Newsmax	1.0	28.2%	-1.3%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
PSIX	Power Solutions International	1.2	-37.5%	-8.7%
GO	Grocery Outlet	0.6	-33.3%	-34.8%
TPB	Turning Point Brands	1.7	-33.1%	-15.4%
HROW	Harrow	1.4	-32.9%	-25.8%
SES	SES AI	0.4	-31.1%	-37.2%
INDI	Indie Semiconductor	0.5	-29.2%	-26.6%
EU	enCore Energy	0.4	-28.9%	-22.6%
DSGR	Distribution Solutions	1.0	-26.1%	-19.4%
TBPH	Theravance Biopharma	0.7	-25.6%	-27.5%
VSCO	Victoria's Secret	3.8	-25.5%	-13.7%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
FSLY	Fastly	3.0	142.4%	97.8%
AAOI	Applied Optoelectronics	6.1	139.5%	174.2%
IOVA	Iovance Biotherapeutics	1.9	110.2%	87.9%
DAWN	Day One Biopharmaceuticals	2.2	97.4%	127.5%
ACHC	Acadia Healthcare	2.3	89.1%	80.5%
NKTR	Nektar Therapeutics	1.3	87.8%	67.2%
CRCL	Circle Internet	23.4	85.1%	28.5%
SOC	Sable Offshore	1.4	73.8%	59.3%
AXTI	AXT	1.4	72.6%	98.0%
KOS	Kosmos Energy	1.2	68.0%	183.2%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
MNKD	MannKind	0.8	-54.8%	-54.0%
EOSE	Eos Energy Enterprises	1.7	-50.6%	-46.5%
GRAL	GRAIL	1.8	-49.2%	-41.3%
FLNC	Fluence Energy	1.9	-49.0%	-25.3%
QURE	uniQure	0.8	-46.5%	-40.4%
CWH	Camping World	0.5	-46.1%	-24.4%
RUN	Sunrun	2.6	-45.3%	-38.4%
NSP	Insperity	0.8	-43.9%	-40.9%
SHLS	Shoals Technologies	1.0	-43.9%	-32.8%
KD	Kyndryl	3.0	-43.6%	-50.3%

Peer Comparisons

Peers to compare with:

Financials

	CATX	LNTH	ATNM	CLRB	LLY	BMY	Median
Name	Perspect.	Lantheus	Actinium.	Cellecta.	Eli Lilly	Bristol-.
Mkt Price	4.97	72.56	1.20	2.76	990.33	60.29	32.63
Mkt Cap	0.4	4.8	0.0	0.0	887.1	122.6	2.6
Rev LTM	0	1,542	0	0	65,179	48,195	771
Op Inc LTM	-95	316	-37	-30	29,696	13,723	143
FCF LTM	-107	349	-25	-30	5,964	12,845	162
FCF 3Y Avg	-59	348	-36	-36	1,075	13,146	156
CFO LTM	-84	390	-25	-30	16,813	14,156	183
CFO 3Y Avg	-38	413	-36	-35	9,957	14,402	189

Growth & Margins

	CATX	LNTH	ATNM	CLRB	LLY	BMY	Median
Name	Perspect.	Lantheus	Actinium.	Cellecta.	Eli Lilly	Bristol-.
Rev Chg LTM	-	0.5%	11.1%	-	44.7%	-0.2%	5.8%
Rev Chg 3Y Avg	-	19.2%	-	-	32.1%	1.5%	19.2%
Rev Chg Q	-	4.0%	-	-	42.6%	1.3%	4.0%
QoQ Delta Rev Chg LTM	-	1.0%	-	-	9.7%	0.3%	1.0%
Op Mgn LTM	-	20.5%	-41,486.7%	-	45.6%	28.5%	24.5%
Op Mgn 3Y Avg	-	25.9%	-	-	37.9%	19.6%	25.9%
QoQ Delta Op Mgn LTM	-	-2.5%	-	-	1.1%	4.7%	1.1%
CFO/Rev LTM	-	25.3%	-27,824.4%	-	25.8%	29.4%	25.6%
CFO/Rev 3Y Avg	-	28.1%	-	-	19.3%	30.5%	28.1%
FCF/Rev LTM	-	22.6%	-27,824.4%	-	9.2%	26.7%	15.9%
FCF/Rev 3Y Avg	-	23.7%	-	-	0.3%	27.9%	23.7%

Valuation

	CATX	LNTH	ATNM	CLRB	LLY	BMY	Median
Name	Perspect.	Lantheus	Actinium.	Cellecta.	Eli Lilly	Bristol-.
Mkt Cap	0.4	4.8	0.0	0.0	887.1	122.6	2.6
P/S	-	3.1	415.9	-	13.6	2.5	8.3
P/EBIT	-3.4	14.3	-1.0	-0.3	29.9	10.9	5.3
P/E	-3.5	20.4	-1.1	-0.5	43.0	17.4	8.5
P/CFO	-4.4	12.2	-1.5	-0.3	52.8	8.7	4.2
Total Yield	-28.7%	4.9%	-92.4%	-216.0%	2.9%	9.9%	-12.9%
Dividend Yield	0.0%	0.0%	0.0%	0.0%	0.6%	4.1%	0.0%
FCF Yield 3Y Avg	-114.3%	7.0%	-60.9%	-5,033.9%	0.0%	12.0%	-30.4%
D/E	0.0	0.1	0.0	0.0	0.0	0.4	0.0
Net D/E	-0.5	0.1	-1.4	-1.4	0.0	0.3	-0.2

Returns

	CATX	LNTH	ATNM	CLRB	LLY	BMY	Median
Name	Perspect.	Lantheus	Actinium.	Cellecta.	Eli Lilly	Bristol-.
1M Rtn	-2.5%	10.1%	3.4%	-7.7%	-10.4%	4.6%	0.4%
3M Rtn	107.1%	14.6%	-16.1%	-26.8%	-1.8%	17.0%	6.4%
6M Rtn	43.6%	32.5%	-24.1%	-44.6%	36.6%	31.2%	31.9%
12M Rtn	84.1%	-27.6%	5.3%	-70.0%	9.3%	5.2%	5.3%
3Y Rtn	5.7%	0.3%	-87.9%	-95.3%	226.0%	1.7%	1.0%
1M Excs Rtn	-0.5%	12.1%	5.5%	-5.6%	-8.3%	6.7%	2.5%
3M Excs Rtn	126.5%	23.0%	-15.6%	-23.6%	-2.4%	21.3%	9.4%
6M Excs Rtn	36.7%	31.2%	-32.7%	-48.2%	30.1%	28.8%	29.4%
12M Excs Rtn	81.1%	-43.1%	-11.0%	-85.1%	-8.1%	-9.5%	-10.2%
3Y Excs Rtn	-34.4%	-71.3%	-159.0%	-165.0%	151.7%	-70.9%	-71.1%

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for Morenull

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022
Period End	9/30/2025	12/31/2024	12/31/2023	12/31/2022
Filing Date	11/10/2025	3/26/2025	3/28/2024	5/1/2023
Key Financials
Total Revenue	0	0	0	4
EBITDA	-105	-78	-39	-7
Operating Income	-95	-67	-41	-8
Net Income	-106	-79	-47	-7
EPS	-1.50	-1.23	-1.74	-0.50
Growth Rates
Total Revenue Growth	-	-	-100.0%	-67.1%
EBITDA Growth	-120.3%	-100.0%	-423.8%	-4.3%
Operating Income Growth	-64.3%	-63.2%	-439.3%	-2.7%
Net Income Growth	-65.9%	-70.5%	-534.1%	-0.9%
Margins
EBITDA Margin	-	-	-	-209.8%
Operating Income Margin	-	-	-	-213.7%
Net Income Margin	-	-	-	-206.5%
Cash & Debt
Total Cash	174	227	9	44
Total Debt	3	4	3	0
Net Debt / (Cash)	-171	-223	-7	-43
Cash Flows
Net Cash from Operations	-84	-18	-37	-6
Free Cash from Operations	-107	-73	-38	-6
Returns to Shareholders
Dividends	0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1
Period End	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023
Filing Date	11/10/2025	8/13/2025	5/12/2025	3/26/2025	11/12/2024	8/13/2024	5/15/2024	3/28/2024	11/14/2023	8/11/2023	5/15/2023
Key Financials Quarterly
Total Revenue	0	0	0	0	0	0	0	0	0	0	0
Ebitda	-25	-21	-17	-42	-14	-11	-11	-11	-9	-9	-9
Operating Income	-28	-24	-22	-21	-19	-14	-13	-12	-10	-10	-10
Net Income	-26	-21	-18	-40	-15	-12	-12	-25	-10	-11	-0
EPS	-0.35	-0.29	-0.25	-0.61	-0.21	-0.18	-0.25	-0.88	-3.70	-0.40	0.00
Key Financials TTM
Total Revenue TTM	0	0	0	0	0	0	0	0	2	4	7
Ebitda TTM	-105	-94	-84	-78	-48	-43	-41	-39	-32	-25	-17
Operating Income TTM	-95	-85	-76	-67	-58	-49	-44	-41	-33	-26	-17
Net Income TTM	-106	-95	-85	-79	-64	-59	-58	-47	-26	-18	-8
Growth Rates Quarterly
Total Revenue Growth	-	-	-	-	-	-	-	-100.0%	-100.0%	-100.0%	-100.0%
EBITDA Growth	-74.7%	-99.1%	-51.4%	-267.9%	-54.7%	-15.2%	-24.3%	-173.4%	-355.6%	-602.4%	-484.6%
Operating Income Growth	-49.5%	-68.5%	-67.9%	-78.6%	-91.1%	-46.2%	-33.5%	-178.0%	-363.0%	-608.9%	-495.7%
Net Income Growth	-71.7%	-83.6%	-48.0%	-62.8%	-46.0%	-5.4%	-3211.1%	-506.6%	-398.4%	-724.5%	76.9%
Margins Quarterly
EBITDA Margin	-	-	-	-	-	-	-	-	-	-	-
Operating Income Margin	-	-	-	-	-	-	-	-	-	-	-
Net Income Margin	-	-	-	-	-	-	-	-	-	-	-
Cash & Debt
Total Cash	174	192	212	227	268	293	181	9	18	28	36
Total Debt	3	4	4	4	4	4	3	3	3	3	2
Net Debt / (Cash)	-171	-188	-208	-223	-264	-289	-178	-7	-15	-26	-34
Cash Flows Quarterly
FCF from Operations	-16	-20	-22	-27	3	-9	14	-9	-10	-8	-10
Cash Flows TTM
FCF from Operations TTM	-84	-65	-54	-18	-1	-14	-13	-37	-30	-22	-16
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-30.2%	-27.5%	-26.7%	-26.5%	-29.1%	-25.0%	-24.0%	-21.2%	-18.4%	-19.5%	-20.5%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-25.7%	-24.5%	-23.2%	-21.7%	-22.5%	-21.3%	-20.4%	-17.3%	-15.8%	-12.9%	-9.2%

Segment Financials

Operating Income by Segment

$ Mil	2024	2023	2022	2021
Total

Assets by Segment

$ Mil	2024	2023	2022	2021
Radiopharmaceutical development segment	341	98
Total	341	98

Price Behavior

Price Behavior

Market Price	$4.97
Market Cap ($ Bil)	0.4
First Trading Date	04/19/2007
Distance from 52W High	-12.0%
	50 Days	200 Days
DMA Price	$3.90	$3.41
DMA Trend	up	up
Distance from DMA	27.4%	45.8%
	3M	1YR
Volatility	170.0%	120.0%
Downside Capture	-186.55	155.05
Upside Capture	263.00	191.67
Correlation (SPY)	8.1%	21.2%

CATX Betas & Captures as of 2/28/2026

	1M	2M	3M	6M	1Y	3Y
Beta	1.91	0.55	1.25	0.05	1.40	1.36
Up Beta	-0.83	3.06	2.26	1.27	1.37	1.15
Down Beta	13.28	2.90	3.33	-0.85	1.08	1.03
Up Capture	635%	238%	374%	104%	355%	490%
Bmk +ve Days	9	20	31	70	142	431
Stock +ve Days	12	25	37	65	129	377
Down Capture	-745%	-513%	-293%	-35%	126%	111%
Bmk -ve Days	12	21	30	54	109	320
Stock -ve Days	8	15	22	53	113	355

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with CATX
CATX	91.9%	120.2%	1.05	-
Sector ETF (XLV)	3.4%	17.5%	0.04	16.7%
Equity (SPY)	16.4%	19.2%	0.66	21.3%
Gold (GLD)	77.1%	26.1%	2.17	-4.4%
Commodities (DBC)	19.6%	17.1%	0.89	-1.9%
Real Estate (VNQ)	3.1%	16.6%	0.01	15.6%
Bitcoin (BTCUSD)	-21.4%	45.5%	-0.39	-0.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with CATX
CATX	-20.5%	100.7%	0.24	-
Sector ETF (XLV)	7.6%	14.5%	0.34	14.3%
Equity (SPY)	13.0%	17.0%	0.60	19.9%
Gold (GLD)	24.2%	17.2%	1.14	3.5%
Commodities (DBC)	11.9%	19.0%	0.51	3.5%
Real Estate (VNQ)	5.0%	18.8%	0.17	13.7%
Bitcoin (BTCUSD)	7.5%	56.8%	0.35	4.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 10-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with CATX
CATX	-8.6%	103.6%	0.33	-
Sector ETF (XLV)	10.4%	16.5%	0.52	11.6%
Equity (SPY)	15.0%	17.9%	0.72	13.0%
Gold (GLD)	15.1%	15.6%	0.80	-0.1%
Commodities (DBC)	9.0%	17.6%	0.43	2.0%
Real Estate (VNQ)	6.1%	20.7%	0.26	8.1%
Bitcoin (BTCUSD)	66.7%	66.8%	1.06	4.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date	2132026
Short Interest: Shares Quantity	9.6 Mil
Short Interest: % Change Since 1312026	0.7%
Average Daily Volume	4.9 Mil
Days-to-Cover Short Interest	2.0 days
Basic Shares Quantity	74.3 Mil
Short % of Basic Shares	12.9%

Returns Analyses

null

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
2/2/2026	33.5%	24.3%	36.4%
11/10/2025	0.0%	-0.5%	21.6%
8/13/2025	-4.3%	-14.1%	-15.1%
3/26/2025	1.3%	-9.7%	5.3%
11/12/2024	-6.9%	-36.5%	-67.5%
8/12/2024	5.7%	17.1%	29.4%
3/28/2024	-0.8%	18.3%	31.7%
11/14/2023	8.5%	11.3%	18.6%
...
SUMMARY STATS
# Positive	8	7	9
# Negative	10	11	9
Median Positive	6.3%	17.1%	21.6%
Median Negative	-4.0%	-9.7%	-15.1%
Max Positive	33.5%	24.3%	69.6%
Max Negative	-27.4%	-36.5%	-67.5%

	Forward Returns
2/2/2026	33.5%	24.3%	36.4%
11/10/2025	0.0%	-0.5%	21.6%
8/13/2025	-4.3%	-14.1%	-15.1%
3/26/2025	1.3%	-9.7%	5.3%
11/12/2024	-6.9%	-36.5%	-67.5%
8/12/2024	5.7%	17.1%	29.4%
3/28/2024	-0.8%	18.3%	31.7%
11/14/2023	8.5%	11.3%	18.6%
8/11/2023	-1.8%	-20.7%	-22.0%
2/16/2023	0.0%	-6.7%	69.6%
9/28/2022	-27.4%	20.7%	7.5%
5/10/2022	-8.7%	1.7%	-4.2%
2/8/2022	7.0%	-0.4%	-9.0%
9/21/2021	-3.7%	-2.0%	-2.0%
5/13/2021	-1.4%	2.2%	8.7%
2/9/2021	-1.1%	-3.4%	-30.7%
9/17/2020	-18.6%	-29.9%	-26.0%
5/12/2020	9.6%	-10.3%	-13.3%
SUMMARY STATS
# Positive	8	7	9
# Negative	10	11	9
Median Positive	6.3%	17.1%	21.6%
Median Negative	-4.0%	-9.7%	-15.1%
Max Positive	33.5%	24.3%	69.6%
Max Negative	-27.4%	-36.5%	-67.5%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
09/30/2025	11/10/2025	10-Q
06/30/2025	08/13/2025	10-Q
03/31/2025	05/12/2025	10-Q
12/31/2024	03/26/2025	10-K
09/30/2024	11/12/2024	10-Q
06/30/2024	08/13/2024	10-Q
03/31/2024	05/15/2024	10-Q
12/31/2023	03/28/2024	10-K
09/30/2023	11/14/2023	10-Q
06/30/2023	08/11/2023	10-Q
03/31/2023	05/15/2023	10-Q
12/31/2022	05/01/2023	10-KT
09/30/2022	11/14/2022	10-Q
06/30/2022	09/28/2022	10-K
03/31/2022	05/13/2022	10-Q
12/31/2021	02/09/2022	10-Q

Insider Activity

Expand for More

#	Owner	Title	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Hunt, Jonathan Robert	Chief Accounting Officer	Direct	Buy	11172025	2.03	11,000	22,295	121,203	Form
2	Williamson, Robert F Iii		RFW3 Revocable Trust	Buy	11142025	2.10	9,498	19,946	20,714	Form
3	Spoor, Johan M	Chief Executive Officer	Direct	Buy	4012025	2.24	22,026	49,384	133,143	Form
4	Spoor, Johan M	Chief Executive Officer	Child #1	Buy	4012025	2.21	4,650	10,288	10,288	Form
5	Williamson, Robert F Iii		Direct	Buy	4012025	2.27	22,192	50,376	160,800	Form

CATX Trade Sentinel

Stock Conviction

null

CONVICTION RATIONALE

null

STOCK ARCHETYPE

null

INVESTMENT THESIS

null

Mechanism: null

Supporting Evidence:

PRIMARY RISK

null

Mechanism: null

Supporting Evidence:

Key KPI Watchlist

KPI	Threshold	Rationale

Core Investment Debate

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Next 6 months: Risks and Catalysts

Timeline	Event & Metric To Watch

Key Events in Last 6 Months

Date	Event	Stock Impact

Risk Management

Position Sizing

null

Diversification Alternatives

How Is The Market Pricing CATX?

What will confirm the thesis

What will damage the thesis

Noise: Real but irrelevant to thesis

Repricing Catalyst

What CATX Makes & Who Pays

TTM figures based on

CATX Evolution: Price Return by Era

① Structure

② Volume / Momentum

③ Catalyst

Combined Score

0 / 12

1 Price Structure & Trend · ▾

2 Momentum ▾

3 Relative Strength vs. SPY ▾

4 Institutional Footprint & Volume ▾

5 Volatility ▾

6 Key Price Levels Range · Vol ▾

7 Earnings Reaction History ▾

8 How the Verdict Is Derived Three Pillars ▾

Pillar	Score
① Structure	0
② Vol / Mom	0
③ Catalyst	0

ℹ Bull Pillars: 0 · Bear Pillars: 0 · Combined Score: 0 →

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Perspective Therapeutics (CATX)

Market Price (3/7/2026): $4.89 | Market Cap: $363.3 MilSector: Health Care | Industry: Life Sciences Tools & Services

Perspective Therapeutics (CATX)

Market Price (3/7/2026): $4.89Market Cap: $363.3 MilSector: Health CareIndustry: Life Sciences Tools & Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Perspective Therapeutics (CATX)

Interactive Breakdown

Better Bets vs. Perspective Therapeutics (CATX)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

FDA Approved Drugs Data

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

CATX Trade Sentinel

null

CONVICTION RATIONALE

STOCK ARCHETYPE

INVESTMENT THESIS

PRIMARY RISK

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Position Sizing

null

Diversification Alternatives

Repricing Catalyst

Industry Resources

External Quote Links

Market Price (3/7/2026): $4.89 | Market Cap: $363.3 Mil
Sector: Health Care | Industry: Life Sciences Tools & Services

Market Price (3/7/2026): $4.89
Market Cap: $363.3 Mil
Sector: Health Care
Industry: Life Sciences Tools & Services